OPEN END TURBO BULL OPTIONSSCHEIN - ASTRAZENECA | Delayed Deutsche Boerse AG 09:11:11 03/06/2024 pm IST | ||
| 4.15 EUR | +4.53% |
|
| 1 month | +3.66% | ||
| 3 months | +136.31% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
| Date | Price | Change |
|---|---|---|
| 03/24/03 | 4.15 | +4.53% |
| 31/24/31 | 3.97 | +4.47% |
| 30/24/30 | 3.8 | +3.54% |
| 29/24/29 | 3.67 | -2.65% |
| 28/24/28 | 3.77 | -8.05% |
Delayed Quote Deutsche Boerse AG
Last update June 03, 2024 at 09:11 pm IST
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HR7PA8 |
| ISIN | DE000HR7PA81 |
| Date issued | 25/05/2021 |
| Strike | 8,820 p |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 0.61 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.73 € |
|---|---|
| Lowest since issue | 0.22 € |
| Spread | 0.03 € |
| Spread % | 0.72% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
155.1
USD
Average target price
172
USD
Spread / Average Target
+10.91%
- Stock Market
- Certificates
- Certificat
